- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
Citigroup analysts say IMS Health (IMS) data show that Gilead's (GILD) hepatitis-C drug sales may be below forecasts.
Cramer says CyberArk Software is doing well but he's avoiding Clovis Oncology.
Cramer says he doesn't understand the obsession some investors have with the Federal Reserve. Forget the Fed.
Shares of Gilead Sciences were lower Wednesday after Leerink cut its price target on the shares.